Literature DB >> 8274304

3-Amino-1-hydroxypropylidine-1-bisphosphonate (AHPrBP) suppresses not only the induction of new, but also the persistence of existing bone-forming surfaces in rat cancellous bone.

J H Tobias1, J W Chow, T J Chambers.   

Abstract

Although bone formation is coupled to resorption in both man and the rat, it is not known whether similar mechanisms are involved in these two species. To investigate this, we have attempted to further characterise the suppression of bone formation by the potent bone resorption inhibitor 3-amino-1-hydroxypropylidine-1-bisphosphonate (AHPrBP) in ovariectomised adult female rats. To see whether AHPrBP affects the activity of preexisting bone forming surfaces, as opposed to preventing the induction of new forming surfaces, three consecutive fluorochrome labels were administered 3, 10, and 17 days prior to sacrifice. The percentage of trabecular surface covered by first and second labels only (arrested surface), second and third labels only (induction surface), and all three labels (persisting surface) were recorded at the secondary spongiosa of the proximal tibial metaphysis. As expected, ovariectomy increased the proportion of induction surfaces, with AHPrBP preventing this increase. However, AHPrBP also reduced the proportion of persisting surfaces, implying inhibition of the activity of preexisting bone-forming surfaces. We conclude that resorption inhibitors such as AHPrBP inhibit bone formation in the rat in a manner which appears inconsistent with the site-specific coupling seen in the adult human skeleton.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8274304     DOI: 10.1016/8756-3282(93)90083-m

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

1.  Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells.

Authors:  Abeer Alasmari; Shih-Chun Lin; Serge Dibart; Erdjan Salih
Journal:  Clin Exp Metastasis       Date:  2016-05-07       Impact factor: 5.150

2.  Mandibular necrosis in beagle dogs treated with bisphosphonates.

Authors:  D B Burr; M R Allen
Journal:  Orthod Craniofac Res       Date:  2009-08       Impact factor: 1.826

Review 3.  Bisphosphonates and bone quality.

Authors:  Michael Pazianas; Stefan van der Geest; Paul Miller
Journal:  Bonekey Rep       Date:  2014-05-07

4.  Activated protein C differentially regulates both viability and differentiation of osteoblasts mediated by bisphosphonates.

Authors:  You-Jin Lee; Jae-Kyo Jeong; Jae-Won Seol; Meilang Xue; Chris Jackson; Sang-Youel Park
Journal:  Exp Mol Med       Date:  2013-02-15       Impact factor: 8.718

5.  Effects of etidronate on the Enpp1⁻/⁻ mouse model of generalized arterial calcification of infancy.

Authors:  Carmen Huesa; Katherine A Staines; Jose Luis Millán; Vicky E MacRae
Journal:  Int J Mol Med       Date:  2015-05-15       Impact factor: 4.101

6.  The effects of zoledronate on the survival and function of human osteoblast-like cells.

Authors:  Kuo-Chin Huang; Chin-Chang Cheng; Po-Yao Chuang; Tien-Yu Yang
Journal:  BMC Musculoskelet Disord       Date:  2015-11-16       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.